secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001104659-22-055272
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q1 net loss $27.4M vs prior-year net income; TAVALISSE sales up 31%
-------------------------------------------------------------------------

- Net loss of $27.4M ($0.16/sh) vs net income of $39.5M ($0.23/sh) in Q1 2021.
- Total revenues $16.7M: TAVALISSE net product sales $16.2M (+31% YoY); contract revenues $0.5M.
- Cash and short-term investments $107.5M at March 31, down from $125.0M at Dec 31, 2021.
- FORWARD Phase 3 wAIHA trial topline data expected mid-2022; potential first-to-market therapy if approved.
- COVID-19 fostamatinib trial enrolled 268 of 308 patients; evaluating completion strategies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922055272/0001104659-22-055272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922055272/tm2214228d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-055272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer